| 30.25 3.61 (13.55%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 36.05  |
1-year : | 42.11 |
| Resists | First : | 30.87 |
Second : | 36.05 |
| Pivot price | 25.38 |
|||
| Supports | First : | 25.24 |
Second : | 21.77 |
| MAs | MA(5) : | 26.76 |
MA(20) : | 25.2 |
| MA(100) : | 21.2 |
MA(250) : | 24.17 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 86.9 |
D(3) : | 84.7 |
| RSI | RSI(14): 78.1 |
|||
| 52-week | High : | 35.95 | Low : | 16.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SMTI ] has closed above the upper band by 29.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 60.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 30.87 - 30.98 | 30.98 - 31.08 |
| Low: | 26.35 - 26.47 | 26.47 - 26.58 |
| Close: | 30.03 - 30.22 | 30.22 - 30.4 |
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
Wed, 29 Jul 2026
SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders - The AI Journal
Wed, 29 Jul 2026
MiMedx plans Sanara MedTech (SMTI) acquisition and prepares S-4 filing - Stock Titan
Wed, 29 Jul 2026
MiMedx agrees to buy Sanara MedTech for $35 a share (SMTI:NASDAQ) - Seeking Alpha
Wed, 29 Jul 2026
MiMedx to buy Sanara MedTech (Nasdaq: SMTI) in $350 million cash-stock deal - Stock Titan
Wed, 29 Jul 2026
Sanara MedTech to Be Acquired by MiMedx in $35-Per-Share Cash-and-Stock Merger - TradingView
Wed, 29 Jul 2026
MiMedx to buy Sanara MedTech (Nasdaq: SMTI) in $350M merger - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 9 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 48 (%) |
| Held by Institutions | 16.4 (%) |
| Shares Short | 378 (K) |
| Shares Short P.Month | 290 (K) |
| EPS | 0.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.76 |
| Profit Margin | -31.3 % |
| Operating Margin | 9.5 % |
| Return on Assets (ttm) | 8.2 % |
| Return on Equity (ttm) | 2.8 % |
| Qtrly Rev. Growth | 18.6 % |
| Gross Profit (p.s.) | 10.9 |
| Sales Per Share | 11.73 |
| EBITDA (p.s.) | 1.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 6 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | 504.16 |
| PEG Ratio | 0 |
| Price to Book value | 39.28 |
| Price to Sales | 2.57 |
| Price to Cash Flow | 43.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|